Atherosclerosis and vascular calcification in chronic renal failure

被引:66
作者
Campean, V
Neureiter, D
Varga, I
Runk, F
Reiman, A
Garlichs, C
Achenbach, S
Nonnast-Daniel, B
Amann, K
机构
[1] Univ Erlangen Nurnberg, Dept Pathol, DE-91054 Erlangen, Germany
[2] Univ Erlangen Nurnberg, Dept Cardiac Surg & Internal Med, DE-91054 Erlangen, Germany
[3] Univ Erlangen Nurnberg, Dept Med 2, DE-91054 Erlangen, Germany
[4] Univ Erlangen Nurnberg, Dept Med 4, DE-91054 Erlangen, Germany
关键词
atherosclerosis; coronary artery sclerosis; chronic renal failure; vascular calcification; plaque calcification; plaque morphology;
D O I
10.1159/000090182
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Cardiovascular complications are a major clinical problem in patients with chronic kidney disease and endstage renal failure; cardiac death accounts for approximately 40-50% of all deaths in these patients. Death from cardiovascular causes is up to 20 times more common in uremic patients than in the general population with the risk being even higher than in patients with diabetes mellitus. A high rate of myocardial infarction and excessive cardiac mortality have repeatedly been documented in patients with kidney disease and renal failure. Not only is the prevalence of myocardial infarction high, but also the case fatality rate is significantly higher in uremic patients with and without diabetes, respectively, compared to nonuremic patients. This is of particular interest since the prevalence of coronary atheroma in uremic patients was shown to be approximately 30% by autopsy and coronary angiography studies. Thus, coronary factors, i.e. atherosclerosis, and non-coronary factors may play an important role in the genesis of cardiac complications in the renal patient. In addition, renal failure recently has also be identified as a predictor of mortality in different stages of peripheral vascular disease. In particular, marked differences in the pathogenesis, morphology and course of atherosclerosis and arteriosclerosis under the conditions of renal failure have been documented. Among others increased plaque formation and particularly higher proportion and intensity of vascular calcification have been found in clinical and autopsy studies. In addition to the so-called classical or traditional risk factors, an important role for nonclassical risk factors such as microinflammation, hyperphosphatemia and oxidative stress has been documented in patients with renal failure and is discussed in detail. Copyright (c) 2005 S. Karger AG, Basel.
引用
收藏
页码:280 / 289
页数:10
相关论文
共 81 条
[1]   Pathophysiology underlying renal disease: Closing in on accelerated atherogenesis in the target [J].
Amann, K ;
Gross, ML ;
Ritz, E .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (06) :1664-1666
[2]   Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia [J].
Amann, K ;
Törnig, J ;
Kugel, B ;
Gross, ML ;
Tyralla, K ;
El-Shakmak, A ;
Szabo, A ;
Ritz, E .
KIDNEY INTERNATIONAL, 2003, 63 (04) :1296-1301
[3]   Effect of antioxidant therapy with dl-α-tocopherol on cardiovascular structure in experimental renal failure [J].
Amann, K ;
Törnig, J ;
Buzello, M ;
Kuhlmann, A ;
Gross, ML ;
Adamczak, M ;
Buzello, M ;
Ritz, E .
KIDNEY INTERNATIONAL, 2002, 62 (03) :877-884
[4]   CHANGES OF VASCULAR ARCHITECTURE-INDEPENDENT OF BLOOD-PRESSURE IN EXPERIMENTAL UREMIA [J].
AMANN, K ;
NEUSUSS, R ;
RITZ, E ;
IRZYNIEC, T ;
WIEST, G ;
MALL, G .
AMERICAN JOURNAL OF HYPERTENSION, 1995, 8 (04) :409-417
[5]  
Amann K, 2001, J AM SOC NEPHROL, V12, P2040, DOI 10.1681/ASN.V12102040
[6]  
Amann K, 2001, J CLIN BAS CARDIOL, V4, P109
[7]   CARDIAC PATHOLOGY IN PATIENTS WITH END-STAGE RENAL-DISEASE MAINTAINED ON HEMODIALYSIS [J].
ANSARI, A ;
KAUPKE, CJ ;
VAZIRI, ND ;
MILLER, R ;
BARBARI, A .
INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 1993, 16 (01) :31-36
[8]   Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study [J].
Block, GA ;
Hulbert-Shearon, TE ;
Levin, NW ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :607-617
[9]  
Boaz M, 2005, CLIN NEPHROL, V63, P98
[10]   Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial [J].
Boaz, M ;
Smetana, S ;
Weinstein, T ;
Matas, Z ;
Gafter, U ;
Iaina, A ;
Knecht, A ;
Weissgarten, Y ;
Brunner, D ;
Fainaru, M ;
Green, MS .
LANCET, 2000, 356 (9237) :1213-1218